Yelak Biru/LinkedIn
Jun 16, 2025, 10:58
Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Yelak Biru, President and Chief Executive Officer at International Myeloma Foundation, posted on X:
“Congratulations Dr. Kaur on this iMMagine-1 study result and presentation at EHA 2025
“Anito-cel utilizes a novel, synthetic antigen-binding domain called the D-Domain, which allows for high transduction efficiency, CAR positivity, and CAR density on the T-cell surface. Coupled with a fast off rate and ability to detach from the BCMA target, [this provides] us with a safe and efficacious product,” lead study author Gurbakhash Kaur said during the presentation.
-
Anito-cel achieved a 97% overall response rate in relapsed/refractory multiple myeloma patients with at least three prior therapies, with a stringent complete response rate of 68%.
-
The novel D-Domain in anito-cel enhances transduction efficiency and safety, contributing to its efficacy in the iMMagine-1 trial.
-
Safety data showed manageable cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, with most cases resolving quickly.
-
Anito-cel is being further evaluated in the phase 3 iMMagine-3 trial against standard-of-care therapy for relapsed/refractory multiple myeloma.”
Title: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Author: Chris Ryan
Read The Full Article at OncLive25.
More posts featuring Yelak Biru.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 16, 2025, 10:58
Jun 16, 2025, 10:48
Jun 16, 2025, 10:28
Jun 16, 2025, 09:39
Jun 16, 2025, 09:33
Jun 16, 2025, 09:14
Jun 16, 2025, 09:02